SCHEMBL5558801

SCHEMBL5558801

COc1cnc(N2CCOCC2)c2sc(NC(=O)c3cccc(N4CCOCC4)c3)nc12

nearest known ligand 0.75

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.75
ADORA1 P30542 2/20 0.75
ADORA3 P0DMS8 1/20 0.60
ADORA2B P29275 1/20 0.60
KMT2A Q03164 2/20 0.57
POLB P06746 1/20 0.57
SAE1 Q9UBE0 1/20 0.54
UBA2 Q9UBT2 1/20 0.54
MEN1 O00255 1/20 0.51
LRRK2 Q5S007 1/20 0.49
MTOR P42345 1/20 0.48
MAPT P10636 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564221 0.91 ADORA2A (0.75) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5565192 0.91 ADORA2A (0.83) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5563614 0.91 ADORA2A (0.86) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5559749 0.90 ADORA2A (0.82) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5564276 0.88 ADORA2A (0.81) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5559252 0.86 ADORA2A (0.79) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5565276 0.86 ADORA2A (0.81) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5559861 0.86 ADORA2A (0.84) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5559889 0.86 ADORA2A (0.75) ADORA2AADORA1ADORA3ADORA2BKMT2A
SCHEMBL5558477 0.86 ADORA2A (0.75) ADORA2AADORA1ADORA3ADORA2BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7273865-B2 Thiazolopyridine HOFFMANN-LA ROCHE INC. (US) 2007-09-25 US claimed
EP-1670805-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-21 EP claimed
WO-2005028484-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-03-31 WO claimed
US-20050065151-A1 Thiazolopyridine HOFFMANN-LA ROCHE INC. 2005-03-24 US claimed
US-7273865-B2 Thiazolopyridine HOFFMANN-LA ROCHE INC. (US) 2007-09-25 US disclosed
EP-1670805-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2006-06-21 EP disclosed
WO-2005028484-A1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-03-31 WO disclosed
US-20050065151-A1 Thiazolopyridine HOFFMANN-LA ROCHE INC. 2005-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065151-A1 Thiazolopyridine ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.